tetano
Editor, Senior Moderator
Lancet Infect Dis
. 2026 Jun 10:S1473-3099(26)00289-6.
doi: 10.1016/S1473-3099(26)00289-6. Online ahead of print.
Seasonal influenza versus COVID-19 hospitalisation risk during the 2025-26 influenza season
Yan Xie[SUP] 1 [/SUP], Taeyoung Choi[SUP] 1 [/SUP], Ziyad Al-Aly[SUP] 2 [/SUP]
Affiliations
PubMed Disclaimer
Conflict of interest statement
The contents of this Correspondence do not represent the views of the US Department of Veterans Affairs or the United States Government. Data is available through the United States Department of Veterans Affairs. Study protocol and statistical code are available from ZA-A (zalaly@gmail.com). During the preparation of this work the authors used ChatGPT 5.5 (OpenAI) and Claude Opus 4.7 (Anthropic) in order to proofread the text. After using these tools, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication. YX and ZA-A report consulting (uncompensated) for Pfizer. All other authors declare no competing interests.
. 2026 Jun 10:S1473-3099(26)00289-6.
doi: 10.1016/S1473-3099(26)00289-6. Online ahead of print.
Seasonal influenza versus COVID-19 hospitalisation risk during the 2025-26 influenza season
Yan Xie[SUP] 1 [/SUP], Taeyoung Choi[SUP] 1 [/SUP], Ziyad Al-Aly[SUP] 2 [/SUP]
Affiliations
- PMID: 42269651
- DOI: 10.1016/S1473-3099(26)00289-6
PubMed Disclaimer
Conflict of interest statement
The contents of this Correspondence do not represent the views of the US Department of Veterans Affairs or the United States Government. Data is available through the United States Department of Veterans Affairs. Study protocol and statistical code are available from ZA-A (zalaly@gmail.com). During the preparation of this work the authors used ChatGPT 5.5 (OpenAI) and Claude Opus 4.7 (Anthropic) in order to proofread the text. After using these tools, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication. YX and ZA-A report consulting (uncompensated) for Pfizer. All other authors declare no competing interests.